



11 June 2020

Company Announcements Office  
Australian Securities Exchange  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

Dear Sir/Madam

#### **NANOCBD DELIVERY RECEIVED AND FIRST PATIENT SUPPLIED**

- Medlab's newest cannabinoid formulation, NanoCBD has been delivered to Australia
- First patient supplied under Government's Special Access Scheme (SAS)
- Intended for treating patients with Chemotherapy Induced Nausea and Vomiting (CINV)\*

Medlab Clinical Limited (ASX: MDC) is extremely pleased to announce that its newest cannabinoid formulation, NanoCBD is available in Australia with the first patient supplied under SAS.

NanoCBD is:

- A CBD only formulation, manufactured in a US, Food and Drug Administration (FDA) approved facility, with analytical work conducted at a US FDA approved testing laboratory.
- The newest product in Medlab's cannabinoid portfolio, and like NanaBis™, shares the same proprietary delivery platform, NanoCelle™.
- Is now available under the Australian Government's Special Access Scheme (SAS) and is intended for treating Chemotherapy Induced Nausea and Vomiting (CINV).
- In parallel to being made available under the SAS, NanoCBD will undergo clinical trials for the treatment of CINV for drug approvals.

Unlike other CBD oils, tablets, or capsules:

- NanoCBD is a submicron spray validated to be 21.29nm delivering 5mg/0.3mL.
- NanoCBD is not subject to known product degradation (1<sup>st</sup> pass metabolism) as it is administered to the oro-buccal membrane and not ingested.
- NanoCBD mechanistically utilises the facial lymphatics for systemic delivery, allowing a more rapid response.

Medlab CEO, Dr Sean Hall said "NanoCBD is a fantastic product to be supplied alongside our lead drug candidate NanaBis™. Unlike NanaBis, NanoCBD is a CBD only product, but like NanaBis™ it is a further example of the optionality of our NanoCelle™ delivery system. NanoCBD will also undertake the clinical trials pathway for an approved drug claim."

"NanoCBD is manufactured to a drug standard, and because it shares a number of similarities to NanaBis™, we believe NanoCBD is well placed to offer a more scientific and medically plausible offering in global markets" Dr Hall added.

Beyond Australia and Hong Kong, where first shipment of NanoCBD has also recently been received, Medlab is focusing discussions on trade expansion in the Northern Hemisphere markets.

*\*CINV or Chemotherapy Induced Nausea and Vomiting, is one of the most feared side effects experienced by patients with cancer<sup>1,2</sup>. Prevalence data indicates that despite the use of medication as a prophylaxis about 44% of patients with experience vomiting within the 120hours following chemotherapy administration, and about 42% will experience nausea.<sup>3</sup>*

For and behalf of the Board.



Dr Sean Hall  
Managing Director

---

**ISSUED FOR:** MEDLAB CLINICAL LTD (ASX: MDC) – [www.medlab.co](http://www.medlab.co)

**FOR FURTHER INFORMATION:** DR SEAN HALL, CEO, MEDLAB CLINICAL  
TEL: +61 2 8203 9520, [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

---

<sup>1</sup> Aapro M., Support Care Cancer, 2018 – “CINV: Still troubling patients after all these years” (Suppl 1); 5-9. DOI: 10.1007/s00520-018-4131-3

<sup>2</sup> <https://www.racgp.org.au/afp/200709/200709feeney.pdf>

<sup>3</sup> Escobar Y., et la, Support Care Cancer, 2015 – “Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) Study” 23(9): 2833-2840. DOI: 10.1007/s00520-015-2809-3